World News
-
WHO validates Australia as first high-income nation to eliminate trachoma
The achievement places Australia among 63 countries globally and 16 in the WHO Western Pacific Region that have eliminated at least one NTD.
-
BioMarin completes US$4.8B acquisition of Amicus Therapeutics to expand rare disease portfolio
The acquisition brings Amicus Therapeutics fully under BioMarin’s global operations, integrating its late-stage and commercial-stage rare disease assets into BioMarin’s established infrastructure.
-
Archimed to take Esperion Therapeutics private in US$1.1B cardiometabolic deal
The transaction is expected to close in the third quarter, after which Esperion will delist from the Nasdaq and operate as a privately held company.
-
-
LEO Pharma acquires Replay to advance their gene therapy pipeline for rare genetic skin diseases
LEO Pharma will gain access to Replay’s proprietary high-payload herpes simplex virus (HSV) delivery platform, an innovative technology designed to deliver large therapeutic genes directly into skin cells.
-
Chiesi strengthens rare disease portfolio with US$1.9B acquisition of KalVista
Under the terms of the agreement, Chiesi will purchase KalVista for US$27 per share, representing a 36% premium over the company’s closing stock price on April 28.
-
Eli Lilly bets US$2.25B on Profluent’s AI-designed gene editing recombinases
The collaboration focuses on multiple research programmes designed to develop and commercialise site-specific recombinases for diseases characterised by severe unmet medical needs.
-
Eli Lilly to acquire Ajax Therapeutics in US$2.3Bdeal to expand rare blood cancer pipeline.
The acquisition gives Lilly access to Ajax’s experimental therapies for myeloproliferative neoplasms (MPNs), a group of rare blood cancers in which the bone marrow produces excessive blood cells.
-
Sun Pharma to acquire Organon for US$11.75B to dominate global women’s health
The acquisition is expected to strengthen Sun Pharma’s global footprint while broadening its presence in women’s health, biosimilars, and established medicines.
-
Moscow’s Center for Diagnostics and Telemedicine slashes radiology report times by 23%
The Moscow-based institution said the improvements are part of a broader effort to modernize radiology workflows and reduce administrative burdens on clinicians.